Program
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003
Its studies are mostly in Multiple Myeloma, led by Innovent Biologics.
Furthest: phase 3, since May 21, 20264 company-led studies, 4 open or runningNext primary completion: Dec 31, 2026 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Innovent Biologics | 44 open or running | phase 3since May 21, 2026 | Oct 9, 2023 | Dec 31, 2026phase 2 · NCT07764861 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 9, 2023First study: phase 2 study in Multiple MyelomaFirst studyNCT06083207 · 116 planned · Australia, China
- Jan 8, 2026Phase 2 study in Multiple MyelomaNCT07336472 · 360 planned · United States
- May 21, 2026Phase 3 study in RecurrencePhase 3 reachedNCT07623798 · 255 planned · China
- Aug 10, 2026Phase 2 study in Multiple MyelomaNCT07764861 · 120 planned · China
Ahead
- Dec 31, 2026Primary completion: phase 2 study in Multiple MyelomaNCT07764861
- Jun 30, 2027Primary completion: phase 2 study in Multiple MyelomaNCT07336472
- May 31, 2029Primary completion: phase 3 study in RecurrenceNCT07623798
TargetBeta
“A T-cell engager (TCE) targeting the tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and G-protein coupled receptor family C group 5 member D (GPRC5D), and the T-cell surface antigen CD3, ”NCIt, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| ramantamig | Johnson & Johnson | phase 3 | 7 |
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07764861Multiple Myeloma · China | 2 | Not yet recruiting | Dec 31, 2026 | 120 |
| NCT07623798Recurrence · China | 3 | Recruiting | May 31, 2029 | 255 |
| NCT07336472Multiple Myeloma · United States | 2 | Recruiting | Jun 30, 2027 | 360 |
| NCT06083207Multiple Myeloma · Australia, China | 2 | Recruiting | Oct 31, 2026 | 116 |
How it is read
Names in the registry
- “IBI3003”, 4 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.